Claims

- (Original) An adjuvant comprising an isolated conjugate of a CD28 and/or CD40
 antibody and at least one antigen wherein said conjugate consists of an oligomeric complex
 wherein the antibody valency of the complex does not exceed an average of about five antibody
 molecules per complex.
- (Previously Presented) An adjuvant according to Claim 1, wherein said conjugate consists of an average of one to four antibody molecules per complex.
- (Previously Presented) An adjuvant according to Claim 2, wherein said complex consists of an average of one to three antibody molecules per complex.
- (Previously Presented) An adjuvant according to Claim 1, wherein said complex consists of one to two antibody molecules per complex.
 - 5-8. (Canceled).
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a Tcell dependent antigen.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a T- cell independent antigen.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is derived from a pathogenic bacterium.

- 12. (Original) An adjuvant according to Claim 11, wherein said antigen is derived from a bacterial species selected from the group consisting of: Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptococcus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis; Shigella flexneri; Escherichia coli; Haemophilus influenzae.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is from a viral pathogen.
- 14. (Previously Presented) An adjuvant according to Claim 13, wherein said antigen is from a viral pathogen from Human Immunodeficiency Virus, Human T Cell Leukaemia Virus, Ebola virus, human papilloma virus, papovavirus, rhinovirus, poliovirus, herpesvirus, adenovirus, Epstein Barr virus, influenza virus, hepatitis B virus or hepatitis C virus.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is from a parasitic pathogen.
- 16. (Previously Presented) An adjuvant according to Claim 15, wherein said antigen is a parasitic pathogen selected from the group consisting of: Trypanosoma spp, Schistosoma spp or Plasmodium spp.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is from a fungal pathogen.
- 18. (Previously Presented) An adjuvant according to Claim 17, wherein said antigen is from a fungal pathogen which is of the genus Candida spp.

- 19. (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a tumour specific antigen or a tumour associated antigen.
- (Original) An adjuvant according to Claim 19, wherein said antigen is a ganglioside antigen.
- (Previously Presented) An adjuvant according to Claim 20, wherein said antigen is MUC-1.
- (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a hormone or hormone receptor.
- (Original) An adjuvant according to Claim 22, wherein said antigen is the N-methyl-D aspartate receptor, or part thereof.
- 24. (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a prion protein.
- (Original) An adjuvant according to Claim 24, wherein said antigen is an amyloid protein.
- 26. (Previously Presented) An adjuvant according to Claim 25, wherein said antigen is amyloid β or part thereof.
- 27. (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is a sperm antigen.
- 28. (Previously Presented) An adjuvant according to Claim 1, wherein said antigen is an addictive drug.

29. (Previously Presented) An adjuvant according to Claim 28, wherein said drug is selected from the group consisting of cocaine, nicotine, and heroin.

30-50. (Canceled).